Silver Book

Silver Book Fact

Pulmonary hypertension is a complication in at least 23% of patients with significant mitral regurgitation due to flail leaflet, and approximately doubles the risk of death and heart failure after diagnosis.

Barbieri A, Bursi F, Grigioni F, et al. Prognostic and Therapeutic Implications of Pulmonary Hypertension Complicating Degenerative Mitral Regurgitation Due to Flail Leaflet. Eur Heart J. 2011; 32(6). https://www.ncbi.nlm.nih.gov/pubmed/20829213

Reference

Title
Prognostic and Therapeutic Implications of Pulmonary Hypertension Complicating Degenerative Mitral Regurgitation Due to Flail Leaflet
Publication
Eur Heart J
Publication Date
2011
Authors
Barbieri A, Bursi F, Grigioni F, et al
Volume & Issue
Volume 32, Issue 6
URL
Read Full Resource

Categories

  • Cost of Disease
  • Human Burden

Publications

Silver Book: Valve Disease Volume

 https://www.silverbook.org/wp-content/uploads/2018/02/SB-Vol-TN.jpg Thumbnail

Related Facts

  • Lifetime risk of atrial fibrillation
    At age 80, the remaining lifetime risk of atrial fibrillation is around 22%.  
  • Venous thromboembolism (VTE) outcomes
    Of the more than 200,000 new cases of venous thromboembolism (VTE) that occur each year, 30% die within 30 days, 20% suffer a sudden death from pulmonary embolism, and around…  
  • The annual total incremental per patient health care expenditures for heart valve disease patients ranged from $1,755 in 1996 to $12,789 in 2011.
     
  • In 2005, there were 81,836,000 physician office visits with a primary diagnosis of cardiovascular disease.  
  • The annual incidence of out-of-hospital cardiac arrests in the U.S. is 0.55/1,000 people–around 166,200.